The rationale for postmastectomy adjuvant radiation is the prevention
of recurrent disease in the chest wall and regional nodes following surgery.
Theoretically, clinically occult disease at the operative site or in regional
nodes could serve as a source for the development of distant metastases.
Therefore, eradication of this disease may have the potential for decreasing
the incidence of distant metastases and improving disease-free and overall
survival. Although the relationship between locoregional control and distant
metastases has generated considerable debate, there is increasing evidence
that all patients with breast cancer do not have systemic disease from
the inception,[1,2] and that there may be a causal relationship between
local control and distant metastases.[3,4]
Using a competing risk approach, Arriagada et al recently analyzed
the results of the Stockholm trial, which randomized 960 women to premastectomy
or postmastectomy radiation vs observation. This analysis recognized the
competing risks for a first event, including locoregional failure, distant
metastases, contralateral breast cancer, non-breast cancer, second malignancy,
and death due to other causes. The addition of radiation significantly
decreased the 15-year cumulative incidence of local failure as a first
event (6% vs 26%; P less .0001) or any event (11% vs 36%; P less .0001).
Radiation did not significantly reduce the incidence of distant metastases
as a first site of failure (29% vs 23%; P = .48), but it did significantly
decrease the overall 15-year cumulative incidence of distant metastases
(37% vs 45%; P = .04). This benefit, however, was limited to the axillary
node-positive patients (54% cumulative incidence with radiation vs 72%
without; P = .01).
Following locoregional recurrence, 66% of the observation group developed
distant metastases, as compared with 82% of the radiation group. Therefore,
radiation decreased the total incidence of distant metastases by decreasing
the incidence of locoregional recurrence as the first site of failure and
the subsequent distant metastases associated with such a recurrence. The
authors estimated a 2% and 4% sur-vival benefit with postmastectomy radiation
at 10 years and 15 years, respectively, for axillary node-negative patients.
For axillary node-positive patients, the survival benefits were 6% at 10
years and 9% at 15 years.
An additional argument in support of postmastectomy radiation is the
prevention of the morbidity associated with uncontrolled locoregional disease.
Delaying radiation until the time of re-currence ultimately results in
long-term control in only 50% to 60% of patients.[5-11]
As a result of the increased use of doxorubicin-based chemotherapy,
che- moendocrine therapy, and high-dose chemotherapy supported by autologous
bone marrow transplantation or peripheral blood progenitor-cell reinfusion,
the role of postmastectomy radiation in the treatment of stages II-III
disease has been challenged. This article will survey the long history
of trials evaluating postmastectomy radiation--both the earlier studies
(then) and more recent trials (now)--to determine whether or not this challenge
Prospective Randomized Trials
Some of the earliest prospective randomized trials of breast cancer
treatment evaluated the role of postmastectomy radiation. These trials
can be divided into two groups: (1) those evaluating the role of radiation
following radical or modified radical mastectomy,[12-20] and (2) those
evaluating the role of radiation following simple mastectomy.[21-26] These
early trials have been criticized for the lack of a consistent randomization
process and inadequate stratification,[12-14] unequal patient distribution
among the treatment arms, the use of confounding ad-juvant therapy,[14,19]
and inadequate radiation in terms of the total dose[12-14,19,27,28] used
and/or the regions treated.[12-14,19]
Despite these criticisms and variations in patient eligibility, the
results achieved were similar. All but one of the trials demonstrated
a decrease in the incidence of locoregional recurrence with radiation.
Moreover, radiation resulted in a decrease in the incidence of distant
metastases in five trials [15,16,19,21,22,26] and a significant improvement
in disease-free survival in four trials.[15,16,19,24,26] None of the trials
showed a significant overall survival benefit for radiation.
A combined analysis of the long-term results of the Oslo and Stockholm
trials found no significant overall or disease-free survival benefit of
radiation therapy in axillary node-negative patients. However, radiation
significantly improved the 10-year disease-free and distant disease-free
survival rates in axillary node-positive patients.
1987 Meta-analysis--A meta-analysis of the mortality results
from eight randomized trials evaluating postmastectomy radiation without
adjuvant chemotherapy was first published in 1987 by Cuzick et al.
The analysis included results of the Manchester I, II and Regional trials,
the National Surgical Adjuvant Breast and Bowel Project (NSABP) B04 trial,
the Stockholm trial, the Oslo I and II trials, the Cancer Research Campaign
trial, the Edinburgh I trial, and an unpublished trial from Heidelberg
that compared radical mastectomy alone to radical mastectomy plus radiation.
In this analysis, radiation therapy afforded no survival benefit for the
first 10 years of follow-up. However, in patients who survived more than
10 years, radiation significantly increased mortality. Data were unavailable
on the specific causes of death.
Subsequent reports from the individual trials[19,20,31-33] indicated
that the increased mortality was related to cardiovascular disease. Patients
with left-sided tumors and those who received orthovoltage or cobalt-60
irradiation of the regional nodes were at greater risk for death due to
The publication of this meta-analysis coincided with the increased use
of doxorubicin-based chemotherapy regimens for axillary node-positive patients
and the initiation of clinical trials for adjuvant therapy in axillary
node-negative women. As a result, interest in and recommendations for postmastectomy
Update of 1987 Meta-analysis--In 1994, Cuzick et al published
an update of the 1987 meta-analysis with specific causes of death for all
of the trials except NSABP B04. The previously reported significant increase
in mortality from all causes in the 10-year survivors was no longer evident.
An increase in cardiac deaths was observed in patients who received radiation,
but this was offset by a decrease in the number of breast cancer-related
deaths, especially in the more recent trials. After 10 years, no significant
differences in mortality were seen among patients who received radiation
following a simple mastectomy. After 15 years, cardiac-related causes of
death were increased in patients who received radiation following a radical
or modified radical mastectomy. The increased mortality was most apparent
in women who were 50 years or more of age and clinically node-negative.
Radiation technique was implicated in these results. Trials that employed
orthovoltage irradiation[20,31] or cobalt-60 irradiation of the internal
mammary nodes[19,33] demonstrated an increased incidence of cardiac deaths.
This meta-analysis suggests that with improvements in radiotherapy technique,
and hence, the avoidance of cardiac morbidity and mortality, postmastectomy
radiation may have the potential for significantly improving survival due
to a decrease in breast cancer-related deaths.
Second Meta-analysis--In 1995, the Early Breast Cancer Trialists'
Collaborative Group published a second meta-analysis of prospective randomized
trials of radiation and surgery for operable breast cancer. This analysis
included 36 trials initiated before 1985, 32 of which evaluated the role
of postmastectomy radiation with or without chemotherapy. Data on cause
of death were available from 28 trials.
Overall mortality was not increased in the patients who received radiation.
Rates of 10-year survival were 63% in axillary node-negative patients who
received radiation vs 62.8% in those who did not. The corresponding numbers
were 47.7% and 46.3% for axillary node-positive patients. Radiation resulted
in a decrease in the number of breast cancer deaths but an increase in
the number of non-breast cancer deaths, which, for the first 2 decades
after treatment, was more evident in women 60 years or more of age. Radiation
reduced the rate of local recurrence by 67%. The authors were unable to
assess the relationship between improved local control and distant metastases
with the available data.
Therefore, two meta-analyses have demonstrated the ability of postmastectomy
radiation to decrease the risk of locoregional recurrence and breast cancer-related
deaths and emphasize the importance of minimizing long-term morbidity with
Risk Factors for Locoregional Recurrence After Mastectomy and No
In surgical series in which adjuvant systemic therapy has not been used,
the risk of a local (chest wall) or regional (axilla, supraclavicular,
or internal mammary node) recurrence following radical or modified radical
mastectomy has been related to primary tumor size and axillary nodal status.[14,35-47]
Patients with primary tumors 5 cm or more in diameter and those with four
or more positive axillary nodes have a 25% to 30% incidence (high risk)
of locoregional recurrence.[14,35-39,41,46] In contrast, patients with
primary tumors 2 cm or less or negative axillary nodes have a 5% to 10%
incidence (low risk) of locoregional recurrence. Patients who have primary
tumors 2 to less than 5 cm in diameter or one to three positive axillary
nodes have a 10% to 15% incidence (intermediate risk) of locoregional recurrence.[14,35,365,39,41,46]
Additional factors that correlate with an increased risk of locoregional
recurrence following mastectomy include young age ( 40 years or less),[35,48,49]
negative estrogen receptors,[50,51] high histologic grade,[44,52,53] and
pectoral fascia involvement.[35,54]
Data are limited regarding the correlation between mastectomy resection
margin status and the risk of a chest-wall recurrence. Axillary node-negative
patients with primary tumors 5 cm or less and a close margin ( 4 mm or
less) have a 6% incidence of locoregional recurrence. Mentzer et al
were unable to correlate the incidence of locoregional recurrence with
margin status in 100 women with stage II breast cancer. Unfortunately,
margin status was assessed grossly in 67% of these patients. None of the
four patients with a positive margin who did not receive radiation experienced
a locoregional recurrence. Locoregional recurrences developed in 3 of 25
patients with a margin 2 mm, or less 5 of 45 patients with a margin 5 mm,
or less and 1 of 33 patients with a margin more than 5 mm.
The most common site for a locoregional recurrence is the chest wall,
either as a single site or a component of multiple sites.[5,6,10,11,56]
Approximately 40% of the chest-wall recurrences involve the mastectomy
scar.[52,57] The second most common site is the supraclavicular region.[5,6,10,11,56]
Axillary recurrences are uncommon in the dissected axilla, especially when
10 or more axillary nodes are removed. The presence of extracapsular
extension does not increase the risk of an axillary recurrence,[59-62]
provided that an adequate dissection has been performed. Internal mammary
node recurrences represent less than 10% of ll locoregional recurrences.[5,6,10,11,56]
The majority of locoregional recurrences postmastectomy occur within
5 years of surgery.[6,11,52,57,63,64] Incidence peaks in the second year.
Montague reported that 34% of locoregional recurrences following mastectomy
occurred after 5 years and 10%, after 10 years.
1. Hellman S: Karnofsky Memorial Lecture: Natural history of small breast
cancer. J Clin Oncol 12:2229-2234, 1994.
2. Hellman S, Weichselbaum R: Radiation oncology and the new biology.
Cancer J Sci Am 1:174-179, 1995.
3. Fowble B: The relationship between local relapse and distant metastases
revisted. Int J Radiat Oncol Biol Phys 30:237-239, 1994.
4. Arriagada R, Rutqvist LE, Mattsson A, et al: Adequate locoregional
treatment for early breast cancer may prevent secondary dissemination.
J Clin Oncol 13:2689-2878,1995.
5. Aberizk WJ, Silver B, Henderson IC, et al: The use of radiotherapy
for treatment of isolated locoregional recurrence of breast carcinoma after
mastectomy. Cancer 58:1214-1218, 1986.
6. Schwaibold F, Fowble BL, Solin LJ, et al: The results of radiation
therapy for isolated local-regional recurrence after mastectomy. Int J
Radiat Oncol Biol Phys 21:299-310, 1991.
7. Bedwinek JM, Lee J, Fineberg B, et al: Prognostic indicators in patients
with isolated local-regional recurrence of breast cancer. Cancer 47:2232-2235,
8. Magno L, Bigrardi M, Micheletti E, et al: Analysis of prognostic
factors in patients with isolated chest wall recurrence of breast cancer.
Cancer 60:240-244, 1987.
9. Janjan NA, McNeese MD, Buzdar AU, et al: Management of locoregional
recurrence of breast cancer. Cancer 58:1552-1556, 1986.
10. Halverson KJ, Perez CA, Kuske RR, et al: Isolated local-regional
recurrence of breast cancer following mastectomy: Radiotherapeutic management.
Int J Radiat Oncol Biol Phys 19:851-858, 1990.
11. Fowble B, Schwaibold F: Local-regional recurrence following definitive
treatment for operable breast cancer, in Fowble B, Goodman RL, Glick JH,
et al (eds): Breast Cancer Treatment, A Comprehensive Guide to Management,
pp 373-403. St. Louis, Mosby, 1991.
12. Easson EC: Post-operative radiotherapy in breast cancer, in Forrest
APM and Kunkler PB (eds): Prognostic Factors in Breast Cancer, pp 118-135.
Edinburgh, E&S Livingstone, 1968.
13. Palmer MK, Ribeiro GG: Thirty-four year follow-up of patients with
breast cancer in clinical trial of postoperative radiotherapy. Br Med J
14. Fisher B, Slack NH, Cavanaugh PJ, et al: Post-operative radiotherapy
in the treatment of breast cancer: Results of the NSABP clinical trial.
Ann Surg 172:711-732, 1970.
15. Rutqvist LE, Cedermark B, Glas U, et al: Radiotherapy, chemotherapy
and tamoxifen as adjuncts to surgery in early breast cancer: A summary
of three randomized trials. Int J Radiat Oncol Biol Phys 15:629-639, 1989.
16. Wallgren A, Arner O, Bergstrom J, et al: Radiation therapy in operable
breast cancer: Results from the Stockholm trial on adjuvant radiotherapy.
Int J Radiat Oncol Biol Phys 12:533-537, 1986.
17. Auquier A, Rutquist LE, Host H, et al: Post-mastectomy megavoltage
radiotherapy: The Oslo and Stockholm trials. Eur J Cancer 28:433-437, 1992.
18. Rutqvist LE, Pettersson D, Johansson H: Adjuvant radiation therapy
versus surgery alone in operable breast cancer: Long-term follow-up at
a randomized clinical trial. Radiother Oncol 26:104-110, 1993.
19. Host H, Brennhoud IO, Loeb M: Post-operative radiotherapy in breast
cancer: Long-term results from the Oslo study. Int J Radiat Oncol Biol
Phys 12:727-732, 1986.
20. Jones JM, Ribeiro GG: Morality patterns over 34 years of breast
cancer patients in a clinical trial of post-operative radiotherapy. Clin
Radiol 40:204-208, 1989.
21. Berstock DA, Houghton J, Haybittle J, et al: The role of radiotherapy
following total mastectomy for patients with early breast cancer. World
J Surg 9:667-670, 1985.
22. Cancer Research Campaign Working Party: Cancer Research Campaign
(King's/Cambridge) trial for early breast cancer: A detailed update at
the tenth year. Lancet i2:55-60, 1980.
23. Forrest APM, Roberts MM, Cant ELM, et al: Simple mastectomy and
pectoral node biopsy: The Cardiff-St. Mary's Trial. World J Surg 1:320-323,
24. Lythgoe JP, Palmer MK: Manchester Regional Breast Study: 5- and
10- year results. Br J Surg 69:693-696, 1982.
25. Turnbull AR, Chant ADB, Buchanan RB, et al: Treatment of early breast
cancer. Lancet ii:7-9, 1978.
26. Fisher B, Redmond C, Fisher ER, et al: Ten year results of a randomized
clinical trial comparing radical mastectomy and total mastectomy with or
without radiation. N Engl J Med 312:674-681, 1985.
27. Brinkley D, Haybittle JL, Houghton J: The Cancer Reserach Campaign
(King's/Cambridge) trial for early breast cancer: An analysis of the radiotherapy
data. Br J Radiol 57:309-316, 1984.
28. Lythgoe JP, Leck I, Swindell R: Manchester regional breast study:
Preliminary results. Lancet 1:744-747, 1978.
29. Fowble B. The role of postmastectomy adjuvant radiotherapy for operable
breast cancer, in Fowble B, Goodman RL, Glick JH, et al (eds): Breast Cancer
Treatment, A Comprehensive Guide to Management, pp 289-309. St. Louis,
30. Cuzick J, Stewart H, Peto H, et al: Overview of randomized trials
of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep
31. Haybittle JL, Brinkley D, Houghton J, et al: Postoperative radiotherapy
and late mortality: Evidence from the Cancer Research Campaign trial for
early breast cancer. Br Med J 298:1611-1614, 1989.
32. Gyenes G, Fornander T, Carlens P, et al: Morbidity of ischemic heart
disease in early breast cancer 15-20 years after adjuvant radiotherapy.
Int J Radiat Oncol Biol Phys 28:1235-1241, 1994.
33. Rutqvist LE, Lat I, Fornander MD: Cardiovascular mortality in a
randomized trial of adjuvant radiation therapy versus surgery alone in
primary breast cancer. Int J Radiat Oncol Biol Phys 22:887-896, 1992.
34. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality
in long-term survivors of breast cancer who participated in trials of radiotherapy.
J Clin Oncol 12:447-453, 1994.
35. Donegan WL, Perez-Mesa CM, Watson FR: A biostatistical study of
locally recurrent breast carcinoma. Surg Gynecol Obstet 122:529-540, 1966.
36. Dao TL, Nemoto T: The clinical significance of skin recurrence after
radical mastectomy in women with cancer of the breast. Surg Gynecol Obstet
37. Baker RR, Montague AC, Childs JN: A comparison of modified radical
mastectomy to radical mastectomy in the treatment of operable breast cancer.
Ann Surg 189:553-559, 1979.
38. Maddox WA, Carpenter JT, Laws HT, et al: A randomized prospective
trial of radical (Halsted) mastectomy versus modified radical mastectomy
in 311 breast cancer patients. Ann Surg 198:207-212, 1983.
39. Rosenman J, Bernard S, Kober C, et al: Local recurrences in patients
with breast cancer treated at the North Carolina Memorial Hospital. Cancer
40. Ahlborn TN, Gump FE, Bodain C, et al: Tumor to fascia margin as
a factor in local recurrence after modified radical mastectomy. Surg Gynecol
Obstet 166:523-526, 1988.
41. Haagensen CD: My personal technique for the Halsted radical mastectomy,
in Haagensen CD (ed): Diseases of the Breast, 3rd ed. pp 872-902. Philadelphia,
WB Saunders, 1986.
42. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival
following radical mastectomy. Cancer 4l:1170-1178, 1978.
43. Overgaard M, Christensen JJ, Johansen H, et al: Post-mastectomy
irradiation in high risk breast cancer patients: Present status of the
Danish Breast Cancer Cooperative Group trials. Acta Oncol 27:707-714, 1988.
44. Hopton DS, Thorogood J, Clayden AD, et al: Histologic grading of
breast cancer: Significance of grade on recurrence and mortality. Eur J
Surg Oncol 15:25-31, 1989.
45. Deck KB, Kern WH: Local recurrence of breast cancer. Arch Surg 111:323-325,
46. Lee YN: Breast carcinoma: Pattern of recurrence and metastasis after
mastectomy. Am J Clin Oncol 7:443, 1984.
47. Crowe JP, Gordon NH, Antunez AR, et al: Local-regional breast cancer
recurrence following mastectomy. Arch Surg 126:429-432, 1991.
48. Lewis D, Rienhoff WFJ: A study of the results of operations for
the cure of cancer of the breast, performed at Johns Hopkins Hospital from
1889 to 1931. Ann Surg 95:336-344, 1932.
49. Matthews RH, McNeese M, Montague ED, et al: Prognostic implications
of age in breast cancer patients treated with tumorectomy and irradiation
or with mastectomy. Int J Radiat Oncol Biol Phys 14:659-663, 1988.
50. Campbell F, Blamey R, Elston C, et al: Estrogen-receptor status
and sites of metastasis in breast cancer. Br J Cancer44:456-461, 1981.
51. Sykes HF, Sim DA, Wong CJ, et al: Local-regional recurrences in
breast cancer after mastectomy and Adriamycin-based adjuvant chemotherapy:
Evaluation of the role of postoperative radiotherapy. Int J Radiat Oncol
Biol Phys 16:641, 1989.
52. Donegan WL. Local and regional recurrence, in Donegan WL and Spratt
JS (eds): Cancer of the Breast, pp 648-663. Philadelphia, WB Saunders,
53. Williams MR, Hinton CP, Todd JH, et al: The prediction of local
or regional recurrence after simple mastectomy for operable breast cancer.
Br J Surg 72:721, 1985.
54. Fowble B, Gray R, Gilchrist K, et al: Identification of a subgroup
of patients with breast cancer and histologically positive nodes receiving
adjuvant chemotherapy who may benefit from postoperative radiotherapy.
J Clin Oncol 6:1107-1117, 1988.
55. Mentzer SJ, Osteen RT, Wilson RE: Local recurrence and the deep
resection margin in carcinoma of the breast. Surg Gynecol Obstet 16:513,
56. Danoff BF, Cola LR, Cantor RI, et al: Locally recurrent breast carcinoma:
The effect of adjuvant chemotherapy on prognosis. Radiology 147:849-952,
57. Pawlias KT, Dockerly MB, Ellis FH: Late locally recurrent carcinoma
of the breast. Ann Surg 148:192-196, 1958.
58. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal
staging and of limited axillary dissection as a determinant of histologic
nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772,
59. Pierce LJ, Oberman HA, Strawderman MH, et al: Microscopic extracapsular
extension in the axilla: Is this an indication for axillary radiotherapy?
Int J Radiat Oncol Biol Phys 33:253-259, 1995.
60. Donegan WL, Stine SB, Samter TG: Implications of extracapsular nodal
metastases for treatment and prognosis of breast cancer. Cancer 72:778-782,
61. Leonard C, Corkill M, Tompkin J, et al: Are axillary recurrence
and overall survival affected by axillary extranodal tumor extension in
breast cancer? Implications for radiation therapy. J Clin Oncol 13:47-53,
62. Perera F, Fisher BJ, Cooke A, et al: Locoregional recurrence and
extranodal extension in patients receiving systemic therapy for axillary
node positive breast cancer (abstract). Int J Radiat Oncol Biol Phys 27:265,
63. Di Pietro S, Bertario L, Piva L: Prognosis and treatment of loco-regional
breast cancer recurrences: Critical considerations on 120 cases. Tumori
64. Shimkin MB, Lucia EL, Low-Beer VA, et al: Recurrent cancer of the
breast: Analysis of frequency, distribution and mortality at the University
of California Hospital, 1918 to 1947, inclusive. Cancer 7:29-34, 1954.
65. Montague ED: Conservative surgery and radiation therapy in the treatment
of operable breast cancer. Cancer 53:700, 1984.
66. Early Breast Cancer Trialists Collaborative Group: Effects of radiotherapy
and surgery in early breast cancer: An overview of the randomized trials.
N Engl J Med 333:1444-1455, 1995.
67. Rao AF, Murthy AK, Hendrickson FR, et al: Analysis of risk factors
for loco-regional failure in stage II breast carcinoma treated with mastectomy
and adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 11:151, 1985.
68. Stefanik D, Goldberg R, Bryne P, et al: Local-regional failure in
patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol
69. Pisanky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor relapse
following mastectomy and adjuvant systemic therapy in patients with axillary
lymph node-positive breast cancer: Impact on clinical, histopathologic
and flow cytometric factors. Cancer 72:1247-1260, 1993.
70. Morrison JM, Howell A, Kelly KA, et al: West Midlands Onocology
Association trials of adjuvant chemotherapy in operable breast cancer:
Results after a median follow-up of 7 years: I. Patients with involved
axillary nodes. Br J Cancer 60:911-918, 1989.
71. Bonadonna G, Valagussa P, Tancini G, et al: Current status of Milan
adjuvant chemotherapy trials for node-positive and node-negative breast
cancer. NCI Monogr 1:45-49, 1986.
72. Richards MA, O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide,
methotrexate and fluorouracil in patients with axillary node-positive breast
cancer: An updae of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039,
73. Misset JL, dipalma M, Delgado M, et al: Adjuvant treatment of node-positive
breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine
versus cyclophosphamide, methotrexate, and fluorouracil: Final report after
a 16 year median follow-up duration. J Clin Oncol 14:1136-1145, 1996.
74. Fisher B, Fisher ER, Redmond C: Ten-year results from the NSABP
clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in
the management of primary breast cancer. J Clin Oncol 4:929-935, 1986.
75. Rubens RD, Knight RK, Fentiman IS, et al: Controlled trial of adjuvant
chemotherapy with melphalan for breast cancer. Lancet i:839-843, 1983.
76. Goldhirsch A, Gelber R: Adjuvant treatment for early breast cancer:
The Ludwig breast cancer studies. NCI Monogr 1:55-70, 1986.
77. Ingle JN, Everson LK, Wieand HS, et al: Randomized trial of observation
versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone
with or without tamoxifen following mastectomy in postmenopausal women
with node-positive breast cancer. J Clin Oncol 6:1388-1396, 1988.
78. Ludwig Breast Cancer Group: Combination adjuvant chemotherapy for
node-positive breast cancer: Inadequacy of a single perioperative cycle.
N Engl J Med 319:677-683, 1988.
79. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing
regimens for the treatment of stage 11 breast cancer: The National Surgical
Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989.
80. Fisher B, Brown A, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide
with and without interval reinduction therapy compared with 6 months of
cyclophosphamide, methotrexate, and fluorouracil in positive-node breast
cancer patients with tamoxifen-nonresponsive tumors: Results from the National
Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496,
81. Budd GT, Green S, O'Bryan RM, et al: Short course FAC-M versus 1
year of CMFVP in node-positive hormone receptor-negative breast cancer:
An intergroup study. J Clin Oncol 13:831-839, 1995.
82. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide,
methotrexate, and fluorouracil with and without doxorubicin in the adjuvant
treatment of resectable breast cancer with one to three positive axillary
nodes. J Clin Oncol 9:1124-1130, 1991.
83. Buzzoni R, Bonadonna G, Valagusso P, et al: Adjuvant chemotherapy
with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in
the treatment of resectable breast cancer with more than three positive
axillary nodes. J Clin Oncol 9:2134-2140, 1991.
84. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating
doxorubicin and CMF regimens in breast cancer with more than three positive
nodes: Ten-year results. JAMA 273:542-547, 1995.
85. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin
regimen and long-term tamoxifen in premenopausal breast cancer patients:
An Eastern Cooperative Oncology Group trial. J Clin Oncol 10: 1848-1856,
86. Gianni AM, Siena S, Bregni M, et al: 5-year results of high-dose
sequential adjuvant chemotherapy in breast cancer with more than 10 positive
nodes. Proc Am Soc Clin Oncol 14:90, 1995.
87. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and
increased total dose of adjuvant chemotherapy for breast cancer: Findings
from NSABP B-22 (abstract). Proc Am Soc Clin Oncol 13:64, 1994.
88. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of
adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl
J Med 330:1253-1259, 1994.
89. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of
high dose combination alkalating agents with ABMT as consolidation after
standard-dose CAF for primary breast cancer involving more than 10 axillary
nodes (Duke/CALGB 8782) (abstract). Proc Am Soc Clin Oncol 14:317, 1995.
90. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy radiotherapy
following adjuvant chemotherapy and autologous bone marrow transplantation
for breast cancer patientswith > 10 positive axillary nodes. Int J Radiat
Oncol Biol Phys 23:1021-1026, 1992.
91. Marks LB, Rosner GL, Prosnitz LR, et al: The impact of conventional
plus high dose chemotherapy with autologous bone marrow transplantation
on hematologic toxicity during subsequent local-regional radiotherapy for
breast cancer. Cancer 74:2964-2971, 1994.
92. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy
and autologous bone marrow support as consolidation after standard-dose
adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143,
93. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant
treatment on first sites of breast cancer relapse. Lancet 343:377-381,
94. Tennrall-Nittby L, Tengrup J, Landberg T: The total incidence of
loco-regional recurrence in a randomized trial of breast cancer TNM stage
II. The South Sweden Breast Cancer Trial. Acta Oncol 32:641-646, 1993.
95. Goldhirsch A, Gelber RD, Castiglione M: Relapse of breast cancer
after adjuvant treatment in premenopausal and perimenopausal women: Patterns
and prognoses. J Clin Oncol 6:89-97, 1988.
96. Rutqvist L, Cedermark B, Fornander T, et al: The relationship between
hormone receptor content and the effect of adjuvant tamoxifen in operable
breast cancer. J Clin Oncol 17:1474-1484, 1989.
97. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen
as a single adjuvant agent in the management of early breast cancer: Analysis
at six years by Nolvadex Adjuvant Trial Organization. Lancet 1:836-840,
98. Aitken RJ, Gaze MN, Rodger A, et al: Arm morbidity within a trial
of mastectomy and either nodal sample with selective radiotherapy or axillary
clearance. Br J Surg 76:568-571, 1989.
99. Kaufmann M, Jonat W, Abel U, et al: Adjuvant randomized trials of
doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/ tamoxifen
andCMF chemotherapy versus tamoxifen in women with node-positive breast
cancer. J Clin Oncol 11:454-460, 1993.
100. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus tamoxifen
versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive,
and estrogen receptor-positive breast cancer patients: A Southwest Oncology
Group Study. J Clin Oncol 12:2078-2085, 1994.
101. Rutqvist LE, Cedermark B, Glas U, et al: Randomized trial of adjuvant
tamoxifen combined with post-operative radiotherapy or adjuvant chemotherapy
in postmenopausal breast cancer. Cancer 66:89-96, 1990.
102. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy vs tamoxifen
vs chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive
breast cancer patients. An update at 7 years of the 1st GROCTA (Breast
Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer
103. Fisher B, Redmond C, Legault-Poisson S, et al: Post-operative chemotherapy
and tamoxifen compared with tamoxifen alone in the treatment of postive-node
breast cancer patients aged 50 years and older with tumors responsive to
tamoxifen: Results from the National Surgical Breast and Bowel Project
B16. J Clin Oncol 8:1005-1018, 1990.
104. Rose C, Anderson J, Axelsson M, et al: A randomized DBCG trial
of adjuvant tamoxifen and radiotherapy vs. tam alone vs. tam and CMF in
postmenopausal breast cancer patients with high risk of recurrence (abstract).
Proc Am Soc Clin Oncol 11:58, 1992.
105. Overgaard M, Christensen JJ, Johansen H, et al: Evaluation of radiotherapy
in high-risk breast cancer patients: Report from the Danish Breast Cancer
Cooperative Group (BBCG 82) trial. Int J Radiat Oncol Biol Phys 19:1121-1124,
106. Pritchard KI, Zee B, Paul N, et al: CMF added to tamoxifen as adjuvant
therapy in postmenopausal women with node-positive estrogen and/or progesterone
receptor-positive breast cancer: Negative results from a randomized clinical
trial (abstract). Proc Am Soc Clin Oncol 13:65, 1994.
107. Pritchard KJ, Paterson AHG, Fine S, et al: A randomized trial of
CMF chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal
women with node positive-estrogen and/or progesterone receptor-positive
breast cancer (abstract). Proc Am Soc Clin Oncol 11: 60, 1992.
108. McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy
and chemotherapy in breast cancer. Br J Surg 73:264-266, 1986.
109. Smith DC, Crawford D, Dykes EH, et al. Adjuvant radiotherapy and
chemotherapy in breast cancer, in Jones SE and Salmon SE (eds): Adjuvant
Therapy of Cancer IV, pp 283-289. Orlando, Grune &Stratton, 1984.
110. Grohn P, Heinonen E, Klefstrom P, et al: Adjuvant postoperative
radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer.
Cancer 54:670-674, 1984.
111. Klefstrom P, Grohn P, Heinonen E, et al: Adjuvant post-operative
radiotherapy, chemotherapy and immunotherapy in stage III breast cancer.
Cancer 60:936-942, 1987.
112. Olson JE, Neuberg D, Pandya K, et al: The management of resectable
stage III breast cancer: The Easter Cooperative Oncology Group Trial (abstract).
Proc Am Soc Clin Oncol 8:23, 1989.
113. Spangenberg JP, Nel CJC, Anderson ID, et al: A prospective study
of the treatment of stage III breast cancer. S Afr J Surg 24:57, 1986.
114. Allen H, Brooks R, Jones SE, et al: Adjuvant treatment for stage
II (node-positive) breast cancer with Adriamycin-cyclophosphamide (AC)
and radiotherapy (XRT), in Salmon SE and Jones SE (eds): Adjuvant Therapy
for Cancer III, pp 453-562. New York, Grune & Stratton, 1981.
115. Griem K, Henderson IC, Gelman R, et al: Post-operative radiotherapy
after adjuvant chemotherapy in breast cancer patients: Results of a randomized
trial. J Clin Oncol 5:1546, 1987.
116. Ragaz J, Jackson SM, Plenderleith IH, et al: Can adjuvant radiotherapy
improve the overall survival of breast cancer patients in the presence
of adjuvant chemotherapy? 10-year analysis of the British Columbia randomized
trial (abstract). Proc Am Soc Clin Oncol 12:60, 1993.
117. Velez-Garcia E, Carpenter IT Jr., Moore M, et al: Postsurgical
adjuvant chemotherapy with or without radiotherapy in women with breast
cancer and positive axillary nodes: A Southeastern Cancer Study Group (SEG)
trial. Eur J Cancer 28A:1833-1837, 1992.
118. Ragaz J, Jackson S, Le N, et al: Can adjuvant locoregional therapy
reduce systemic recurrences in stage I-II breast cancer patients? Recurrence
analysis of the British Columbia randomized trial (abstract). Proc Am Soc
Clin Oncol 15:121, 1996.
119. Dombernowsky P, Zedeler K, Hansen M, et al: Randomized trial of
adjuvant CMF and radiotherapy vs. CMF alone vs. CMF and tamoxifen in pre
and menopausal stage 11 breast cancer (abstract). Proc Am Soc Clin Oncol
120. Dombernowsky P, Hansen PS, Mouridsen HT, et al: Randomized trial
of adjuvant CMF and radiotherapy vs. CMF alone vs. CMF and tamoxifen in
pre and menopausal stage II breast cancer (abstract). Eur J Cancer 3OA:S28,
121. Ahmann DL, O'Fallon JR, Scanlon PW, et al: A preliminary assessment
of factors associated with recurrent disease in a surgical adjuvant clinical
trial for patients with breast cancer with special emphasis on the aggressiveness
of therapy. Am J Clin Oncol 5:371-381, 1982.
122. Martinez A, Ahmann D, O'Fallon J, et al: An interim analysis of
the randomized surgical adjuvant trial for patients with unfavorable breast
cancer (abstract). Int J Radiat Oncol Biol Phys 10: 150, 1985.
123. Suit HD, Westgate SJ: Impact of improved local control on survival.
Int J Radiat Oncol Biol Phys 12:453-458, 1986.
124. Rose C, Hansen M, Dombernowsky P, et al: A randomized DBCG trial
of adjuvant tamoxifen and radiotherapy vs. tamoxifen alone vs. tamoxifen
and CMF in postmenopausal breast cancer patients with high risk of recurrence
(abstract). Eur J Cancer 30A: S28, 1994.
125. Overgaard M, Hansen SR, Engelholm S, et al: Postmastectomy radiotherapy
and adjuvant systemic treatment in high-risk breast cancer patients. Eur
J Cancer 30A:S28, 1994.
126. Mouridsen HT, Rose C, Overgaard M, et al: Adjuvant treatment of
postmenopausal patients with high risk primary breast cancer: Results from
the Danish adjuvant trials DBCG 77C and DBCG 82C. Acta Oncol 27:699-705,
127. Fowble B, Glick J, Goodman R: Radiotherapy for the prevention of
local-regional recurrence in high risk patients post mastectomy receiving
adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 15:627-631, 1988.
128. Uematsu M, Bernstein BA, Recht A, et al: Long-term results of post-operative
radiation therapy following mastectomy with or without chemotherapy in
stage I-III breast cancer. Int J Radiat Oncol Biol Phys 25:765-770, 1993.
129. Ung O, Langlands AO, Barraclough B, et al: Combined chemotherapy
and radiotherapy for patients with breast cancer and extensive nodal involvement.
J Clin Oncol 13:435-443, 1995.
130. Buzdar AU, Kau S-W, Hertobagyi GM, et al: Clinical course of patients
with breast cancer with 10 or more positive nodes who were treated with
doxorubicin-containing adjuvant therapy. Cancer 69:448-452, 1992.
131. Fowble B, Yeh I-T, Schultz DJ, et al: The role of mastectomy in
patients with stage I-II breast cancer presenting with gross multifocal
or multicentric disease or diffuse microcalcifications. Int J Radiat Oncol
Biol Phys 27:567-573, 1993.
132. Halverson KJ, Taylor ME, Perez CA, et al: Regional nodal management
and patterns of failure following conservative surgery and radiation therapy
for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 26:593-599,
133. Buchholz TA, Austin-Seymour MM, Moe RE, et al: Effect of delay
in radiation in the combined modality treatment of breast cancer. Int J
Radiat Oncol Biol Phys 26:23-35, 1993.
134. Buzdar AU, Kau SW, Smith TL, et al: The order of administration
of chemotherapy and radiation and its effect on the local control of operable
breast cancer. Cancer 71:3680-3684, 1993.
135. Klefstrom P, Nuortio L, Taskinen E: Postoperative radiation therapy
and adjuvant chemoimmunotherapy in breast cancer: Aspects of timing and
immune competence. Acta Radiol 25:161-166, 1986.
136. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide,
methotrexate, and fluorouracil in node-positive breast cancer: The results
of 20 yrs. of follow-up. N Eng J Med 322:901-906, 1995.
137. Lara Jimenez P, Garcia Puche J, PedrazaV: Adjuvant combined modality
treatment in high-risk breast cancer patients: Ten-year results. A293 (abstract).
5th EORTC Breast Cancer Working Conference, Leuven, Belgium, 1991.
138. Brufman G, Sulkes A: Effect of timing of onset of chemotherapy
on relapse-free survival in stage II breast cancer (abstract). Proc Am
Soc Clin Oncol 5:62, 1986.
139. Shapiro CL, Recht A: Late effects of adjuvant therapy for breast
cancer. J Natl Cancer Inst Monograph 16:101-112, 1994.
140. Abrams JS, Phillips PH, Friedman MA: Meeting highlights: A reappraisal
of research results for the local treatment of early stage breast cancer.
J Natl Cancer Inst 87:1837-1845, 1995.
141. Werner RS, McCormick B, Petrek J, et al: Arm edema in conservatively
managed breast cancer: Obesity is a major predictive factor. Radiology
142. Valagussa P, Zambetti M, Biasi S, et al: Cardiac effects following
adjuvant chemotherapy and breast irradiation in operable breast cancer.
Ann Oncol 5:209-216, 1994.
143. Harrigan P, Otis D, Recht A, et al: The effect of adjuvant radiation
therapy on cardiac events in breast cancer patients treated with doxorubicin
(abstract). Proc Am Soc Clin Oncol 14:102, 1995.
144. Hughes-Davies L, Sacks D, Rescigno J, et al: Serum cardiac troponin
T levels during treatment of early stage breast cancer. J Clin Oncol 13:2582-2584,
145. Plunkett ME, Bernstein BA, Costello P, et al: Use of spiral CT
in the assessment of cardiac structures for planning 3D volumetric radiation
treatment of the breast (abstract). Radiology 189:355, 1993.
146. Janjan NA, Gillin MT, Prows J, et al: Dose to the cardiac vascular
and conduction systems in primary breast irradiation. Med Dos 14:81-87,
147. Fuller SA, Haybittle JL, Smith REA, et al: Cardiac doses in postoperative
breast irradiation. Radiother Oncol 25:19-24, 1992.
148. Danoff BF, Galvin JM, Cheng E, et al: The clinical application
of CT scanning in the treatment of primary breast cancer, in Ames FC, Blumenschein
GR, Montague ED (eds): Current Controversies in Breast Cancer. pp 391-397.
Austin, University of Texas Press, 1984.
149. Early Breast Cancer Trialists Collaborative Group: Systemic treatment
of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized
trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.
Lancet 339:1-15, 71-85, 1992.
150. Allred DC, Clark GM, Tandon AK, et al: HER2/neu in node-negative
breast cancer: Prognostic significance of overexpression influenced by
the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992.
151. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast
cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol
152. Muss HB, Thor AD, Berry DA, et al: C-erb B-2 expression and response
to adjuvant therapy in women with node-positive early breast cancer. N
Engl J Med 330:1260-1266, 1994.
153. Nordenskjold B, Stal 0, Skoog L, et al: S-phase fraction and c-erb
b-2 expression related to the survival benefit from adjuvant chemotherapy
of breast cancer (abstract). Proc Am Soc Clin Oncol 13:67, 1994.
154. Jansson T, Inganas M, Sjogren S, et al: P53 status predicts survival
in breast cancer patients treated with or without postoperative radiotherapy:
A novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751,
155. Fisher B, Redmond C, and others for the National Surgical Adjuvant
Breast and Bowel Project: Systemic therapy in node-negative patients: Updated
findings from NSABP clinical trials. J Natl Cancer Inst Monograph 11:105-115,
156. Mansour EG, Eudey L, Termey DC, et al: Chemotherapy versus observation
in high-risk node-negative breast cancer patients. J Natl Cancer Inst Mongraph
157. Goldhirsch A, Castiglione M, Gelber RD (for the International Breast
Cancer Study Group, formerly Ludwig Group): A single perioperative adjuvant
chemotherapy course for node-negative breast cancer: Five-year results
of trial V. J Natl Cancer Inst Monograph 11:89-96, 1992.
158. Zambetti M, Benadonno G, Valagusso P, et al: Adjuvant CMF for node-negative
and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst
Monograph 11:77-83, 1992.
159. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International
(Ludwig) Breast Cancer Study Group trials I-IV: 15-year follow-up. Ann
Oncol 5:717-724, 1994.
160. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus melphalan
for operable breast cancer with positive axillary nodes: 10-year results
of a Southwest Oncology Group study. J Clin Oncol 7:1229-1238, 1989.
161. Falkson HE, Gray RG, Wolberg WH, et al: Adjuvant trial of 12 cycles
of CMFPT followed by observation or continuous tamoxifen versus 4 cycles
of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative
Oncology Group Phase III study. J Clin Oncol 8:599-607, 1990.
162. Levine MN, Gent M, Hyrniuk WM, et al: A randomized trial comparing
12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
J Clin Oncol 8:1217-1225, 1990.
163. Rivkin SE, Gree S, Metch B, et al: One versus 2 years of CMFVP
adjuvant chemotherapy in axilary node-positive and estrogen receptor-negative
patients: A Southwest Oncology Group study. J Clin Oncol 11:1710-1716,
164. Tormey DC, Weinberg VE, Holland JF, et al: A randomized trial of
five- and three-drug chemotherapy and chemoimmunotherapy in women with
operable node-positive breast cancer. J Clin Oncol 1:138, 1983.
165. Wood WC, Weiss RB, Tormey DC, et al: A randomized trial of CMF
versus CMFVP as adjuvant chemotherapy in women with node-positive stage
II breast cancer: A CALGB Study. World J Surg 9:714, 1985.
166. Buzdar AU, Blumenshein GR, Smith TL, etal: Adjuvant chemotherapy
with fluorouracil, doxorubicin and cyclophosphamide, with or without irradiation
in operable breast cancer: A prospective randomized trial. Cancer 53:384,
167. Muss HB ,Cooper MR, Brockschmidt JK, et al: A randomized trial
of chemotherapy (L Pam vs CMF) and irradiation for node-positive breast
cancer: Eleven-year follow-up of a Piedmont Oncology Association trial.
Breast Cancer Res Treat 19:77-84, 1991.
168. Buzdar A, Smith T, Blumenschein G, et al: Adjuvant chemotherapy
with fluorouracil, doxorubicin, and cyclophosphamide (FAC) for stage II
or III breast cancer: Five-year results, in Salmon SE and Jones SE (eds):
Adjuvant Therapy for Cancer, pp 419-426. New York, Grune & Stratton,
169. Blomqvist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy,
adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen
in stage II breast cancer: Long-term follow-up results of a randomized
trial. Br J Cancer E16:1171-1176, 1992.